Optimisation of disease assessments in juvenile idiopathic arthritis

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S126-S130

  Consolaro, Alessandro ^a   Schiappapietra, Benedetta ^a   Dalprà, Sara ^a   Calandra, Serena ^a   Martini, Alberto ^a   Ravelli, Angelo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Composite disease activity score; Juvenile idiopathic arthritis; Outcome measures; Paediatric rheumatology; Patient reported outcomes; Response criteria

Indexed keywords

ARTHRALGIA; ARTICLE; CONSTRUCT VALIDITY; DISEASE ACTIVITY; HUMAN; JOINT SWELLING; JUVENILE ARTHRITIS DAMAGE INDEX; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE; JUVENILE RHEUMATOID ARTHRITIS; LIMITED MOBILITY; MORNING STIFFNESS; MUSCULOSKELETAL DISEASE ASSESSMENT; PAIN INTENSITY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; TREATMENT RESPONSE; VALIDATION PROCESS; AGE; ARTHRITIS, JUVENILE; CLINICAL PATHWAY; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; STANDARDS;

AGE FACTORS; ARTHRITIS, JUVENILE; CLINICAL TRIALS AS TOPIC; CRITICAL PATHWAYS; DATABASES, FACTUAL; HUMANS; PATIENT OUTCOME ASSESSMENT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 84922392792     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. BREWER EJ, Jr., GIANNINI EH: Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design. J Rheumatol 1982; 9: 109-13.
2. GIANNINI EH, BREWER EJ, Jr.: Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data. J Rheumatol 1982; 9: 114-22.
3. BRUNNER HI, RAVELLI A: Developing outcome measures for paediatric rheumatic diseases. Best Pract Res Clin Rheumatol 2009; 23: 609-24.
4. FILOCAMO G, CONSOLARO A, SOLARI N et al.: Recent advances in quantitative assessment of juvenile idiopathic arthritis. Ann Paediatr Rheum 2012; 1: 84-96.
5. LUCA NJC, FELDMAN BM: Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol 2014; 28: 331-50.
6. GIANNINI EH, RUPERTO N, RAVELLI A, LOVELL DJ, FELSON DT, MARTINI A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
7. BRUNNER HI, LOVELL DJ, FINCK BK, GIANNINI EH: Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002; 29: 1058-64.
8. CONSOLARO A, RAVELLI A: It is worth including assessment of disease activity state in juvenile arthritis clinical trials. Arthritis Care Res (Hoboken) 2013; 65: 1207-10.
9. LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763-9.
10. RUPERTO N, LOVELL DJ, CUTTICA R et al.: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096-106.
11. LOVELL DJ, RUPERTO N, GOODMAN S et al.: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.
12. RUPERTO N, LOVELL DJ, QUARTIER P et al.: Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-91.
13. YOKOTA S, IMAGAWA T, MORI M et al.: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
14. de BENEDETTI F, BRUNNER HI, RUPERTO N et al.: Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-95.
15. RUPERTO N, BRUNNER HI, QUARTIER P et al.: Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-406.
16. WALLACE CA, RUPERTO N, GIANNINI E: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
17. WALLACE CA, HUANG B, BANDEIRA M, RAVELLI A, GIANNINI EH: Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 3554-62.
18. RAVELLI A, MARTINI A: Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006; 24: S105-S110.
19. WALLACE CA, GIANNINI EH, HUANG B, ITERT L, RUPERTO N: American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 929-36.
20. MAGNI-MANZONI S, RUPERTO N, PISTORIO A et al.: Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008; 59: 1120-7.
21. WELLS G, BOERS M, SHEA B et al.: MCID/ Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. J Rheumatol 2003; 30: 1110-1.
22. CONSOLARO A, RUPERTO N, BAZSO A et al.: Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66.
23. NORDAL EB, ZAK M, AALTO K et al.: Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis 2012; 71: 1122-7.
24. CONSOLARO A, BRACCIOLINI G, RUPERTO N et al.: Remission, minimal disease activity and acceptable symptom state in juvenile idiopathic arthritis. Arthritis Rheum 2012; 64: 2366-74.
25. CONSOLARO A, RUPERTO N, BRACCIOLINI G et al.: Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. Ann Rheum Dis 2014; 73: 1380-3.
26. CONSOLARO A, CALANDRA S, ROBBIANO C, RAVELLI A: Treating juvenile idiopathic arthritis according to JADAS-based targets. Ann Paediatr Rheum 2014; 3: 4-10.
27. BULATOVIC CM, de VRIES LD, VASTERT SJ, HEIJSTEK MW, WULFFRAAT NM: Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2014; 53: 307-12.
28. CONSOLARO A, NEGRO G, LANNI S, SOLARI N, MARTINI A, RAVELLI A: Toward a treat-totarget approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S157-S162.
29. HORNEFF G, BECKER I: Definition of improvement in juvenile idiopathic arthritis using the Juvenile Arthritis Disease Activity Score. Rheumatology (Oxford) 2014; 53: 1229-34.
30. RAVELLI A, VIOLA S, RUPERTO N, CORSI B, BALLARDINI G, MARTINI A: Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis 1997; 56: 197-200.
31. RUPERTO N, GIANNINI EH: Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Ann Rheum Dis 1996; 55: 73-5.
32. DUFFY CM: Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Pediatr Clin North Am 2005; 52: 359-72.
33. BRUNNER HI, GIANNINI EH: Health-related quality of life in children with rheumatic diseases. Curr Opin Rheumatol 2003; 15: 602-12.
34. FILOCAMO G, CONSOLARO A, FERRARI C, RAVELLI A: Introducing new tools for assessment of parent-and child-reported outcomes in paediatric rheumatology practice: a work in progress. Clin Exp Rheumatol 2013; 31: 964-8.
35. FILOCAMO G, CONSOLARO A, SCHIAPPAPIETRA B et al.: Parent and child acceptable symptom state in juvenile idiopathic arthritis. J Rheumatol 2012; 39: 856-63.
36. CONSOLARO A, RUPERTO N, PISTORIO A et al.: Development and initial validation of composite parent-and child-centered disease assessment indices for juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 1262-70.
37. McERLANE F, BERESFORD MW, BAILDAM EM et al.: Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis 2013; 72: 1983-8.
38. CONSOLARO A, NEGRO G, GALLO MC et al.: Defining criteria for disease activity states in non-systemic juvenile idiopathic arthritis based on a three-variable Juvenile Arthritis Disease Activity Score. Arthritis Care Res (Hoboken) 2014.
39. CONSOLARO A, LANNI S, MARTINI A, RAVELLI A: Adalimumab-induced clinical remission in refractory and long-standing systemic juvenile idiopathic arthritis: case report. Ann Paediatr Rheum 2014; 3: 29-34.
40. VIOLA S, FELICI E, MAGNI-MANZONI S et al.: Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 2092-102.
41. RAVELLI A: The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials. J Rheumatol 2008; 35: 553-7.
42. MAGNI-MANZONI S, MALATTIA C, LANNI S, RAVELLI A: Advances and challenges in imaging in juvenile idiopathic arthritis. Nat Rev Rheumatol 2012; 27: 329-36.
43. LANNI S, WOOD M, RAVELLI A, MAGNIMANZONI S, EMERY P, WAKEFIELD RJ: Towards a role of ultrasound in children with juvenile idiopathic arthritis. Rheumatology (Oxford) 2013; 52: 413-20.
44. McQUEEN FM: Magnetic resonance imaging in early inflammatory arthritis: what is its role? Rheumatology (Oxford) 2000; 39: 700-6.
45. GRASSI W, FILIPPUCCI E, FARINA A, SALAFFI F, CERVINI C: Ultrasonography in the evaluation of bone erosions. Ann Rheum Dis 2001; 60: 98-103.
46. PINCUS T, MANDELIN AM, SWEARINGEN CJ: Flowsheets that include MDHAQ physical function, pain, global, and RAPID3 scores, laboratory tests, and medications to monitor patients with all rheumatic diseases: an electronic database for an electronic medical record. Rheum Dis Clin North Am 2009; 35: 829-xi.